|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.40/--
|
企业价值
17.41M
|
资产负债 |
每股账面净值
-0.26
|
现金流量 |
现金流量率
--
|
损益表 |
收益
1.93M
|
每股收益
0.38
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/01/11 17:18 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs). |